Bevacizumab targets a protein called vascular endothelial growth factor-A (VEGF-A) and slows tumour growth and proliferation by preventing tumour angiogenesis, thereby depriving GBM cells of nutrient uptake (7). The gene discussed is VEGFA; the disease is glioblastoma.